Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: An analysis of primary and secondary prevention trials

The Lancet

Volumn 385, Issue 9984, 2015, Pages 2264-2271

  Mega, Jessica L ^a   Stitziel, Nathan O ^b   Smith, J Gustav ^c,j   Chasman, Daniel I ^a   Caulfield, Mark J ^d   Devlin, James J ^e   Nordio, Francesco ^a   Hyde, Craig L ^f   Cannon, Christopher P ^a   Sacks, Frank M ^g   Poulter, Neil R ^h   Sever, Peter S ^h   Ridker, Paul M ^a   Braunwald, Eugene ^a   Melander, Olle ⁱ   Kathiresan, Sekar ^j   Sabatine, Marc S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^g CHANNING LABORATORY   (United States)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

ⁱ LUND UNIVERSITY   (Sweden)

^j BROAD INSTITUTE OF MIT AND HARVARD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY RISK; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; ISCHEMIC HEART DISEASE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNSTABLE ANGINA PECTORIS; CORONARY DISEASE; GENETICS; META ANALYSIS; NUMBERS NEEDED TO TREAT; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME;

CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NUMBERS NEEDED TO TREAT; PRIMARY PREVENTION; RECURRENCE; RISK ASSESSMENT; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84934277268     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61730-X     Document Type: Article

References (43)

1. ME Marenberg, N Risch, LF Berkman, B Floderus, U de Faire Genetic susceptibility to death from coronary heart disease in a study of twins N Engl J Med 330 1994 1041 1046
2. DM Lloyd-Jones, BH Nam, RB D'Agostino Sr et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring JAMA 291 2004 2204 2211
3. S Kathiresan, D Srivastava Genetics of human cardiovascular disease Cell 148 2012 1242 1257
4. P Deloukas, S Kanoni, C Willenborg et al. Large-scale association analysis identifies new risk loci for coronary artery disease Nat Genet 45 2013 25 33
5. SE Humphries, JA Cooper, PJ Talmud, GJ Miller Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men Clin Chem 53 2007 8 16
6. S Kathiresan, O Melander, D Anevski et al. Polymorphisms associated with cholesterol and risk of cardiovascular events N Engl J Med 358 2008 1240 1249
7. S Ripatti, E Tikkanen, M Orho-Melander et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses Lancet 376 2010 1393 1400
8. G Thanassoulis, GM Peloso, MJ Pencina et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham Heart Study Circ Cardiovasc Genet 5 2012 113 121
9. A Brautbar, LA Pompeii, A Dehghan et al. A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies Atherosclerosis 223 2012 421 426
10. MF Hughes, O Saarela, J Stritzke et al. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts PLoS One 7 2012 e40922
11. E Tikkanen, AS Havulinna, A Palotie, V Salomaa, S Ripatti Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease Arterioscler Thromb Vasc Biol 33 2013 2261 2266
12. A Ganna, PK Magnusson, NL Pedersen et al. Multilocus genetic risk scores for coronary heart disease prediction Arterioscler Thromb Vasc Biol 33 2013 2267 2272
13. I Buysschaert, KF Carruthers, DR Dunbar et al. A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study Eur Heart J 31 2010 1132 1141
14. E Wauters, KF Carruthers, I Buysschaert et al. Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study Eur Heart J 34 2013 993 1001
15. V Tragante, PA Doevendans, HM Nathoe et al. The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk Eur Heart J 34 2013 2896 2904
16. RS Patel, FW Asselbergs, AA Quyyumi et al. Genetic variants at chromosome 9p21 and risk of first versus subsequent coronary heart disease events: a systematic review and meta-analysis J Am Coll Cardiol 63 2014 2234 2245
17. G Berglund, S Elmstahl, L Janzon, SA Larsson The Malmo Diet and Cancer Study. Design and feasibility J Intern Med 233 1993 45 51
18. PM Ridker, E Danielson, FA Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
19. PS Sever, B Dahlof, NR Poulter et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
20. FM Sacks, MA Pfeffer, LA Moye et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
21. CP Cannon, E Braunwald, CH McCabe et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
22. H Schunkert, IR Konig, S Kathiresan et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease Nat Genet 43 2011 333 338
23. TJ Wang Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction Circulation 123 2011 551 565
24. C Baigent, L Blackwell, J Emberson et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681
25. B Mihaylova, J Emberson, L Blackwell et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
26. F Taylor, MD Huffman, AF Macedo et al. Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
27. JD Berry, A Dyer, X Cai et al. Lifetime risks of cardiovascular disease N Engl J Med 366 2012 321 329
28. U Laufs, WS Weintraub, CJ Packard Beyond statins: what to expect from add-on lipid regulating therapy? Eur Heart J 34 2013 2660 2665
29. F Basso, GD Lowe, A Rumley, AD McMahon, SE Humphries Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS) Arterioscler Thromb Vasc Biol 22 2002 599 604
30. OA Iakoubova, CH Tong, AP Chokkalingam et al. Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS Arterioscler Thromb Vasc Biol 26 2006 2763 2768
31. BD Chiodini, MG Franzosi, S Barlera et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study Eur Heart J 28 2007 1977 1983
32. AH Maitland-van der Zee, A Lynch, E Boerwinkle et al. Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study Pharmacogenet Genomics 18 2008 651 656
33. MS Sabatine, L Ploughman, KL Simonsen et al. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy Arterioscler Thromb Vasc Biol 28 2008 562 567
34. OA Iakoubova, MS Sabatine, CM Rowland et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study J Am Coll Cardiol 51 2008 449 455
35. AH Maitland-van der Zee, BJ Peters, AI Lynch et al. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study Pharmacogenet Genomics 19 2009 338 344
36. OA Iakoubova, M Robertson, CH Tong et al. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study Eur J Cardiovasc Prev Rehabil 17 2010 455 461
37. Y Li, MS Sabatine, CH Tong et al. Genetic variants in the KIF6 region and coronary event reduction from statin therapy Hum Genet 129 2011 17 23
38. A Brautbar, D Covarrubias, J Belmont et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia Atherosclerosis 219 2011 737 742
39. H Akao, E Polisecki, K Kajinami et al. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly Atherosclerosis 220 2012 456 462
40. D Shiffman, S Trompet, JZ Louie et al. Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy PLoS One 7 2012 e38240
41. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
42. JL Mega, DA Morrow, A Brown, CP Cannon, MS Sabatine Identification of genetic variants associated with response to statin therapy Arterioscler Thromb Vasc Biol 29 2009 1310 1315
43. JC Hopewell, S Parish, A Offer et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study Eur Heart J 34 2013 982 992